Daiichi Sankyo Co., Ltd. is a global, research‑driven pharmaceutical company headquartered in Tokyo, Japan. Formed in 2005 through the merger of Daiichi Pharmaceutical and Sankyo, the company discovers, develops, manufactures, and markets prescription medicines with a primary focus on oncology, alongside cardiovascular and other therapeutic areas.
Daiichi Sankyo is known for its work in antibody–drug conjugates (ADCs) and other targeted therapies, integrating small‑molecule chemistry, bioconjugation, and biologics to advance cancer treatments. Its R&D and manufacturing network spans Japan, Europe, the United States, and Asia, supporting activities from early discovery and clinical development to sterile and commercial production of finished dosage forms.
For the chemical and life sciences value chain, the company’s capabilities include active pharmaceutical ingredient (API) synthesis, linker–payload technologies for ADCs, and high‑containment and aseptic manufacturing under global quality and regulatory standards. Daiichi Sankyo also collaborates with industry partners to co‑develop and supply innovative oncology therapies worldwide.